Pulmonary Edema Market to Experience an Upswing to Rise at a Breathless CAGR of 7.2% During Forecast 2017-2023
Market Analysis:
The
global Pulmonary Edema Market
is projected to grow at an astounding 7.2% CAGR during the
forecast period (2017-2023). Pulmonary edema is a medical condition that
takes place when fluid gets accumulated in the air sacs of the lungs called the
alveoli which results in the difficulty to breathe. It interferes with the gas
exchange thereby resulting in respiratory failure. Pulmonary edema has some
alternate names- pulmonary congestion, lung water or lung congestion. It is of
two types namely acute or sudden onset and chronic that occurs gradually over
time. The acute pulmonary edema symptoms include shortness of breath
accompanied with wheezing and coughing (that often produces frothy, pink
sputum). Here the treatment will vary resting on the severity. However,
medications and supplemental oxygen mount the backgrounds in most pulmonary
edema treatment methods.
There are many factors that is
driving the growth of the pulmonary edema market. Some of these factors as per the
Market Research Future (MRFR) report include rising prevalence of pulmonary
edema as well as diseases such as heart disease, kidney failure and others,
growing geriatric population, changing lifestyles, extensive R&D activities
and growing awareness regarding preventive therapies. On the contrary, lack of
awareness regarding the disease and low per capita healthcare cost in the low
and middle-income countries are estimated in hampering the growth of the pulmonary
edema market.
Key Players:
·
Canon
Medical Systems Corporation
·
Hitachi
Medical Corporation
·
Siemens
Healthcare GmbH
·
Koninklijke
Philips N.V.
·
Medtronic
·
Vitaltec
Corporation
·
Lupin
Pharmaceuticals
·
Alcaliber
S.A
·
BD
·
Edwards
Lifesciences Corporation
·
ARGON
MEDICAL
·
Pfizer
Inc
Market Segmentation:
·
Market Research Future report offers an all-inclusive segmental
analysis of the pulmonary edema market on the basis of type,
diagnosis, treatment and end-user.
·
Based on type, it is segmented into
cardiogenic edema and others.
·
Based on diagnosis, the pulmonary edema market is segmented
into imaging, blood tests and others.
·
Based on treatment, it is segmented into
suction catheter, morphine, preload reducers and others. The preload reducers
are further segmented into diuretics, nitroglycerin and others.
·
Based on end users, the pulmonary edema market is segmented
into retail pharmacies, academic institutes, hospitals and clinics and others.
Regional Analysis:
Based on region,
the pulmonary
edema market covers growth opportunities and latest trends across North
America, Europe, Asia Pacific and the Middle East and Africa. Of these, North
America will rule the market due to high per capita healthcare cost and a
healthcare sector that is well-developed. Besides, the existence of developed
economies such as Canada and the US and the presence of some global players
here is anticipated to drive the growth of the pulmonary edema market in this
region.
Europe holds the second biggest
share followed by the APAC region. The factors that have contributed to the
growth of the market in Europe include the accessibility of funds for research
and the existence of developed economies such as Germany, Italy and France in
this region. Besides, the rising geriatric population here will further drive
the growth of the market.
The market in the APAC region is the fastest growing owing to the
existence of developing economies such as China and India here. Besides,
increasing healthcare expenditure coupled with favorable government policies will
fuel the growth of the pulmonary edema market. The Indian healthcare sector is
the largest with regards to employment and revenue, as stated by the Indian
Brand Equity Foundation, 2018. Besides, the industry is anticipated to expand
at a stellar rate due to rising expenditure by both private and public players.
Comments
Post a Comment